Pancreatic Cancer Research

ResearcherCasa Sollievo della SofferenzaActive in the last 2 years

Evaristo Maiello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3890-3435; OpenAlex author ID A5036855364, A5046559582. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 21

  1. Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. Co-author DOI 10.1007/s13304-026-02598-7↗
  2. Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and B… Co-author DOI 10.1002/cam4.71450↗
  3. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  4. A powerful machine learning approach to identify interactions of differentially abundant gut microbial subsets in patients with metastatic and non-metastatic p… Co-author DOI 10.1080/19490976.2024.2375483↗
  5. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  6. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  7. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  8. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study. Co-author DOI 10.1186/s10020-023-00600-1↗
  9. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  10. Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspe… Co-author DOI 10.1016/j.semcancer.2021.11.007↗
  11. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  12. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  13. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  14. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). First author DOI 10.3390/curroncol28030164↗
  15. Clinical Significance of Circulating miR-1273g-3p and miR-122-5p in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00044↗
  16. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  17. Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer. Co-author DOI 10.1038/s41598-018-34597-z↗
  18. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the… Co-author DOI 10.1080/14737167.2018.1464394↗
  19. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Co-author DOI 10.1155/2018/7530619↗
  20. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clini… Co-author DOI 10.1186/s12967-014-0248-4↗
  21. Combined modality treatments in pancreatic cancer. Last author DOI 10.1517/14728222.2012.662959↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiziana Pia Latiano · 8 shared papers, 2012–2025 · strength 1.05
  2. Francesco Perri · 4 shared papers, 2022–2025 · strength 0.75
  3. Valerio Pazienza · 4 shared papers, 2014–2025 · strength 0.61
  4. Annacandida Villani · 3 shared papers, 2022–2025 · strength 0.58
  5. Concetta Panebianco · 3 shared papers, 2022–2025 · strength 0.58
  6. Andrea Fontana · 4 shared papers, 2014–2024 · strength 0.49
  7. Giampaolo Tortora · 3 shared papers, 2018–2026 · strength 0.41
  8. Francesca Tavano · 4 shared papers, 2014–2023 · strength 0.39
  9. Michèle Milella · 2 shared papers, 2018–2026 · strength 0.29
  10. Michele Reni · 2 shared papers, 2018–2026 · strength 0.29
  11. Angelo Andriulli · 3 shared papers, 2014–2020 · strength 0.22
  12. Ilaria Tarantino · 1 shared paper, 2026 · strength 0.22
  13. Giuseppe Quero · 1 shared paper, 2026 · strength 0.22
  14. Sergio Alfieri · 1 shared paper, 2026 · strength 0.22
  15. Carlo Fabbri · 1 shared paper, 2026 · strength 0.22
  16. Ugo Boggi · 1 shared paper, 2026 · strength 0.22
  17. Roberto Salvia · 1 shared paper, 2026 · strength 0.22
  18. Guido Giordano · 2 shared papers, 2018–2021 · strength 0.19
  19. Vanja Vaccaro · 1 shared paper, 2021 · strength 0.11
  20. Caterina Vivaldi · 1 shared paper, 2021 · strength 0.11
  21. Elisa Giommoni · 1 shared paper, 2021 · strength 0.11
  22. Francesco Di Costanzo · 1 shared paper, 2021 · strength 0.11
  23. Lorenzo Antonuzzo · 1 shared paper, 2021 · strength 0.11
  24. Serena Pillozzi · 1 shared paper, 2021 · strength 0.11
  25. Tommaso Mazza · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.